Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional salvianolic acid B (very low certainty).
1 finding from 1 review
Rate of maxillary molar intrusion for correction of anterior open bite · Adolescents and adults with malocclusion undergoing fixed orthodontic appliance treatment
1 finding from 1 review
Two studies (62 participants), not pooled. Abellan 2021: no significant difference in molar intrusion at 3 months (1.25 vs 1.72 mm) or 6 months (1.09 vs 1.28 mm), nor rate per month. Hasan 2022: increased intrusion…
2 studies · 62 participants
GRADE not reported
Awareness of prolapse: Laparoscopic versus open · women with apical vaginal prolapse
Sacral colpopexy: laparoscopic showed no clear difference in awareness of prolapse: Laparoscopic versus open compared with alternative approach (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Neutropenia · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether one dose or dose regimen of a foetal haemoglobin inducer changes neutropenia (WBC < 1 × 103/μL, ANC < 0.5 × 103/μL) compared with another dose or dose regimen of the same foetal haemoglobin inducer (very low certainty).
1 finding from 1 review
Thrombocytopenia (platelet count < 50 × 103/μL) · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether one dose or dose regimen of a foetal haemoglobin inducer changes thrombocytopenia (platelet count < 50 × 103/μL) compared with another dose or dose regimen of the same foetal haemoglobin inducer (very low certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neutropenia · women with recurrent epithelial ovarian cancer
Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).
1 finding from 1 review
Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores... · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).
1 finding from 1 review
Intervention not reported
Letter with fixed appointment versus letter with open invitation to make appointment: uptake of screening · women for cervical screening
The intervention probably leads to higher letter with fixed appointment versus letter with open invitation to… (moderate certainty).
1 finding from 1 review